{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:33:46Z","timestamp":1763706826474,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by high immunogenicity which makes it particularly suitable for immune checkpoint inhibitors (ICIs) treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report the case of a 53-year-old man with metastatic DM successfully treated with the combination of anti-CTLA-4 and anti-PD-1 antibodies, who developed serious immune-related adverse events (irAEs). The primary tumor was characterized by absent PD-L1 expression and no-brisk lymphocytes infiltration. NGS showed absence of BRAF mutation, a high tumor mutational burden, and an UV-induced DNA damage signature. Metastatic lesions regressed rapidly after few cycles of ICIs until complete response, however the patient developed serious irAEs including hypothyroidism, adrenal deficiency, and acute interstitial nephritis which led to the definitive suspension of treatment. Currently, the patient has normal renal functionality and no disease relapse after 26 months from starting immunotherapy, and after 9 months from its definitive suspension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Efficacy and toxicity are two sides of the same coin of high sensitivity to ICIs in DM. For this reason, these patients should be closely monitored during ICIs therapy to promptly identify serious side effects and to correctly manage them.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1369531","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:15:08Z","timestamp":1715328908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?"],"prefix":"10.3389","volume":"15","author":[{"given":"Teresa","family":"Squicciarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Apollonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Zambetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamaria","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"De Roma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.lba100","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1909021116","article-title":"Intragenomic variability and extended sequence patterns in the mutational signature of ultraviolet light","volume":"116","author":"Lindberg","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02543-6","article-title":"Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies","volume":"69","author":"Kerepesi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00439","article-title":"Association of baseline tumor-specific neoantigens and CD8(+) T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors","volume":"8","author":"Kerepesi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.11.001","article-title":"Response to \"Ipilimumab (Yervoy) and the TGN1412 catastrophe\"","volume":"217","author":"Curran","year":"2012","journal-title":"Immunobiology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02751-0","article-title":"Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution","volume":"70","author":"Kleef","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: A randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01711","article-title":"Cost savings and increased access with ultra-low-dose immunotherapy","volume":"41","author":"Mitchell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: A multicenter retrospective study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708195","article-title":"Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: A systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592609","article-title":"Durable complete response in a melanoma patient with unknown primary, associated with sequential and severe multi-organ toxicity after a single dose of CTLA-4 plus PD-1 blockade: A case report","volume":"10","author":"Matull","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7567","article-title":"Multiorgan immune-related adverse events during treatment with atezolizumab","volume":"18","author":"Kichenadasse","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-center experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/biomedicines10102424","article-title":"Checkpoint inhibitors immunotherapy in metastatic melanoma: when to stop treatment","volume":"10","author":"De Risi","year":"2022","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2023.03.020","article-title":"Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup","volume":"187","author":"Rubatto","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:15:16Z","timestamp":1715328916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2024.1369531"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369531","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1369531"}}